Aerocrine AB (OMX Nordic Exchange: AERO) announces that Health Canada’s Therapeutic Products Directorate has authorized Aerocrine’s latest NIOX MINO® for use in identifying allergic airway ...
SOLNA, Sweden & ANTONY, France--(BUSINESS WIRE)--Aerocrine AB (STO:AERO.B) and Stallergenes S.A (Euronext Paris CAC small) today announce the signing of an exclusive multi-year distribution agreement ...
SOLNA, Sweden, 12 February 2009 - Aerocrine AB (OMX Nordic Exchange: AERO) has reported the recent publication of a UK study evaluating the effect of routine inflammation measurement in asthma. The ...
Aerocrine secured $50 million in financing to market the Niox Mino.--Courtesy of Aerocrine Sweden's Aerocrine has secured $50 million in combined debt and equity financing, money the company will use ...
March 11, 2008 — The US Food and Drug Administration (FDA) has granted 510(k) clearance for a handheld device for the measurement of airway inflammation, an intraosseous infusion system for use in ...
Aerocrine AB, a medical technology company focused on the improved management and care of patients with inflammatory airway diseases, has signed an distribution agreement with Shanghai Pharmaceuticals ...
Aerocrine AB (STO:AEROB) announces today that Japanese health authorities have cleared the use of Aerocrine's FeNO-measuring device NIOX VERO® as a tool for assessing patients with allergic airway ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Roberto Gradnik, Chief Executive OfficerTel. +33 1 55 59 20 04orChristian Thiry, Chief Financial OfficerTel. +33 1 55 59 20 95e-mail: orPavie Finance: Lucile de FraguierTel. +44 208 248 2793e-mail: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results